EpiCept Corporation Announces Initiation of Phase 2B Study of Azixa(TM) for Front-Line Treatment of Glioblastoma Multiforme by Myrexis

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News: EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) today reported that Myrexis, Inc. has initiated a controlled two-arm Phase 2b clinical study of Azixa™ as a front-line treatment for glioblastoma multiforme (GBM). Azixa™, a vascular disruption agent with potent anti-cancer activity, was discovered by EpiCept as part of its ASAP technology platform and licensed to Myrexis.